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Vaccination coverage in Brazil 
(2000 to 2010)
THE IMPACTS OF VACCINATION IN BRAZIL
Children vaccination coverage by type of vaccination
Over 70 million 
children successfully 
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Implementation of the MMR 
vaccine and DTP + Hib vaccine 




























THE IMPACTS OF VACCINATION IN BRAZIL
Number of cases for tetanus – accidental and neonatal
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Incidence per 100K inhabitants
Number of  accidental tetanus per year  
Source: Sinan/SVS/MS, data in 25/08/11Ministry of Health, Brazil , 2010.
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Emergency Plan for 
high-risk counties
Strengthening 



































THE IMPACTS OF VACCINATION IN BRAZIL
The number of severe cases and deaths due to influenza A H1N1 has been falling 
since March 2010
























Deaths from pandemic influenza (H1N1)

















* epidemiological week of onset of symptoms
Source: Sinan/SVS, Ministry of Health, Brazil , 2010.
Strategy
Brazil decided in the mid 80's to become self-sufficient 
in vaccines and immunization programs
BRAZIL HAS BECOME AN INTERNATIONAL REFERENCE IN IMMUNIZATION
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Decision
This was a State decision rather than a government decision
Too important to depend on availability and pricing
Why
Eradication
PNI – Founded in 1973
NATIONAL IMMUNIZATION PROGRAM (PNI) IN BRAZIL
 194 MM inhabitants 
 43 types of immunobiological
 26 Vaccines
PNI – General Information of Brazil (2011)
 Smallpox
 Poliomyelitis
 Measles (autocne transmission)











 13 sera from animal  
 4 sera from human
 77% produced in Brazil
 ~ 300 MM doses of vaccines per year
 30 K vaccination  rooms
 Expansion of national self-sufficiency
Source: SVS/Ministry of Health, National Immunizatation Program, Brazil, 2011.
 In 1901 Butantan was established to produce serum against the bubonic plague
 Vital Brazil, the first director, investigated antivenoms against snake bites 
 Currently, Butantan is the main public producer of 
vaccines, antivenoms, antitoxins in Latin America
 Fully dedicated to develop scientific research and production of immunobiological
products for public health
WHAT DO WE ARE?
BUTANTAN – A PUBLIC INSTITUTION OF THE STATE GOVERNMENT OF SÃO PAULO
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RESEARCH & DEVELOPMENT LABORATORIES
 ~21 scientific labs
 ~180 Researchers
 85% are PhD
 1 Biotechnology Center
 Multiple laboratories
 1 Hospital (10 hospital beds)
 1 Central Animal Facility
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 Training programs (PAP)
 Graduate studies in Toxicology
 Masters and PhDs












Venom Composition by Transcriptomics and Proteomics
Plasma fractioning by 
chromatography




 7 Main Industrial Plants (Buildings)
 Anaerobic vaccines (tetanus and botulinic ) 
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and Anatoxin Purification
 Biological control




 Blood Products (under construction)
 Control, Serums, Formulation and Filling
 6 Pilot Plants





‘Market Share’ per Suppliers(1)
(2010)
WHAT DO WE DO?
















1Source: Ministry of Health, 2010
Note: Part of Butantan’s production was sent to other 
Institutes, such as Biomanguinhos. Not computed in the 
analysis
‘Market Share’ per Suppliers(1)
(2010)
Snakes AV
WHAT DO WE DO?









Scorpion AV Spider AV Caterpillar AV
Tetanus AT Diphitheria AT AntiRabies
Botulism AB & E
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Note: Part of Butantan’s production was sent to other 





Sabin Vaccine Institute - George Washington University Necator - Schistosoma
Children’s Hospital Harvard - PATH Pneumococcus (cellular)
VACCINES WITH EXTERNAL COOPERATION
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Infectious Diseases Research Institute Visceral Leishmaniosis (for dogs)
Ludwig Institute for Cancer Research Adjuvant for ovarian cancer
BR Foods Lung Surfactant
Universidade de São Paulo – Medical School
Recombinant OncoBCG for bladder 
cancer
Institut Pasteur – Paris / Novartis - Siena / 
Albert Einstein College of Medicine
Recombinant BCG-Pertussis
AGENDA
 OVERVIEW OF IMMUNIZATION PROGRAM IN BRAZIL AND
INSTITUTO BUTANTAN
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 BUTANTAN DEVELOPMENTS
Area Vaccines Projects 1




 Recombinant onco BCG
 Silica nanostructure mesoporous – vaccine 
antigens encapsulated
WHAT DO WE WANT TO DO?
Presentation and discussion of vaccines projects
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 Streptococcus pneumoniae (cellular - SPWCV)
 BCG-Pertussis
Vaccines – Basics R&D  Leptospira
Techtransfer  Several vaccines under negociation
1 Not exhaustive
 Composition
– B.pertussis whole cell with lower content of
LPS
 Production Technology
– Organic extraction of the cells to reduce LPS 




– To make available an alternative vaccine for 
Pertussislow vaccine
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content
 ~ 70% reduction of LPS 
– “in line” process without additional costs
 Phase of Development
– Pre-clinical studies performed in Butantan and
in the Netherlands Institute Vaccine (NIV) 
– Phase I (2012) – Brazil
immunization of children, adolescent, 
pregnant women and adults
Pertussislow vaccine - technical and scientific aspects 
New developments in Pertussis Vaccines with Appropriate technologies
Whole Cell Pertussis
Vaccine












 ~ 70% reduction of LPS 
 Less reactogenic
 Low cost














– BpMPLA derived from LPS of B.pertussis
 Production Technology
– Purification of B.pertussis followed by LPS 
hydrolises




– To optimize immunolgical response of pre-
exisiting and new vaccines
Adjuvant – Monophosphoryl lipid A (BpMPLA)
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 Phase of Development
– Scale-up 
– To increase production capacity
BpMPLA
– Clinical trial






 Hepatites B + BpMPLA
 Seazonal Influenza + BpMPLA
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 Composition
– Recombinant BCG strain expressing the S1 
subunit 1 of Pertussis toxin
 Production Technology
– The rBCG-Pertussis strain was produced 
Product - Recombinant BCG – Pertussis Butantan –
Recombinant BCG-Pertussis  
Neonate vaccine / Onco BCG for Bladder cancer
 Challenges:
– To produce the vaccine by fermentation or 
static culture
– To perform the clinical trials
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without antibiotic resistance gene1
 Appropriate for use in humans 
 Phase of Development
– Production of GMP lots
 Objectives: 
– To immunize infants 0 – 2 months of age
– To make available a new vaccine for bladder 
cancer 
Nota: 1 Auxotrofic strain for lysine is complemented with a plasmid that 
expresses the deleted gene plus the heterologous gene – S1PT
Recombinant BCG-Pertussis - technical and scientific aspects
Protection of neonate mice immunized with rBCG-S1PT against intracerebral
























ONE DOSE AT DAY 5
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Challenge dose at day 21: 106 CFU Challenge dose at day 21: 3x107 CFU






















Source: Microbes Infect.10:198-202 (2008) 
Silica (SBA-15)
Immunogenic complex formed by vaccinal antigens encapsulated by 
nanostructured mesoporous silica
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 The SBA-15 possesses hexagonal porous uniformity (3.1 – 6.5 nm)
 Thermal and hydrothermal stability 




– Sorotypes: G1, G2, G3, G4 e G9
 Technology of Production
– Cell substrate: Vero cells
Product – Pentavelent Rotavirus Vaccine 
 Challenges:
– To perform Phase II and III - non-inferiority 
study
– To find funding for:
 Clinical Trial and laboratory assay – Phase II / III
Butantan –
Rotavirus Vaccine
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– Reassortment – Human/bovine
– Nº lots produced: 09 (6 K doses)
 Phase of Development
– Phase I: 2010 
 Results: safe and immunogenic
– Phase II: 2013
• Partnership
– NIH / PATH / BNDES
 Objective: 
– Pentavalent low cost vaccine
 Composition
– Attenuated virus
– Sorotypes: DEN1, DEN2, DEN3, DEN4
 Technology of Production
– Cell substrate: Vero cells
Product – Tetravalent Dengue Vaccine Butantan –
Dengue Vaccine
 Challenges:
– To speed up Phase I, II, and  III – (to avoid 
non-inferiority study)
– To find funding for:
 Clinical Trial and Laboratory assay – Phase III
 Equipment 
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– Recombinant DNA technology
– Chimeric
– Nº lots produced: 06 (17 K doses)
 Phase of Development
– Phase I and II: 2012/2013
• Partnership
– NIH - DVI (Dr. Steve Whitehead) 
– BNDES / FAPESP
 Plant
 Maintenance of “The Global Solutions for 
Infectious Disease” support
– To define target population for immunization
– Production capacity x national and 
international demand
 Objective: 
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Av. Vital Brasil, 1500 - Butantã
São Paulo – SP
Zip Code - 05503-900
(+ 55 11) 3726.7222
www.butantan.gov.br
